Endomedix Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC
  • (In Progress)

  • Latest Deal Amount
  • $4.6M

  • Investors
  • 10

Endomedix General Information

Description

Developer of a biomaterials platform designed to develop absorbable medical products for surgical applications. The company offers patented polysaccharide chemistry, absorbable hemostatic materials, and biomaterial technologies for brain and spinal surgery, enabling hospitals and healthcare providers to improve bleeding control and reduce surgery-related complications.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Normal Avenue
  • CELS 404
  • Montclair, NJ 07043
  • United States
+1 (848)
Primary Industry
Surgical Devices
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1 Normal Avenue
  • CELS 404
  • Montclair, NJ 07043
  • United States
+1 (848)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endomedix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 05-Sep-2025 $4.6M In Progress Pre-Clinical Trials
10. Accelerator/Incubator 28-Oct-2025 Completed Pre-Clinical Trials
9. Accelerator/Incubator 08-Sep-2023 Completed Pre-Clinical Trials
8. Later Stage VC 09-Dec-2023 Completed Pre-Clinical Trials
7. Seed Round 23-Jul-2021 Completed Pre-Clinical Trials
6. Seed Round 01-Nov-2018 Completed Pre-Clinical Trials
5. Grant 29-Jun-2017 Completed Pre-Clinical Trials
4. Seed Round 07-Feb-2015 Completed Pre-Clinical Trials
3. Accelerator/Incubator $1.4M Completed Startup
2. Accelerator/Incubator $1.4M Completed Startup
To view Endomedix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Endomedix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biomaterials platform designed to develop absorbable medical products for surgical applications. The comp
Surgical Devices
Montclair, NJ
5 As of 2026

Deerfield, IL
 

Princeton, NJ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Endomedix Competitors (3)

One of Endomedix’s 3 competitors is Baxter International, a Corporation company based in Deerfield, IL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Baxter International Corporation Deerfield, IL
Integra LifeSciences Holdings Corporation Princeton, NJ
Pfizer Corporation New York, NY
You’re viewing 3 of 3 competitors. Get the full list »

Endomedix Patents

Endomedix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3883615-A1 Methods and compositions for achieving hemostasis and stable blood clot formation Active 19-Nov-2018
EP-3883615-A4 Methods and compositions for achieving hemostasis and stable blood clot formation Active 19-Nov-2018
EP-3883615-B1 Methods and compositions for achieving hemostasis and stable blood clot formation Active 19-Nov-2018
EP-4403194-A2 Methods and compositions for achieving hemostasis and stable blood clot formation Active 19-Nov-2018
EP-4403194-A3 Methods and compositions for achieving hemostasis and stable blood clot formation Active 19-Nov-2018 C08B37/003
To view Endomedix’s complete patent history, request access »

Endomedix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endomedix Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Texas Medical Center Venture Capital Minority
Central Texas Angel Network Angel Group Minority
Neuvation Ventures Venture Capital Minority
Symbiotic Ventures Venture Capital Minority
Ignite Healthcare Network Accelerator/Incubator
You’re viewing 5 of 10 investors. Get the full list »

Endomedix FAQs

  • When was Endomedix founded?

    Endomedix was founded in 2005.

  • Where is Endomedix headquartered?

    Endomedix is headquartered in Montclair, NJ.

  • What is the size of Endomedix?

    Endomedix has 5 total employees.

  • What industry is Endomedix in?

    Endomedix’s primary industry is Surgical Devices.

  • Is Endomedix a private or public company?

    Endomedix is a Private company.

  • What is Endomedix’s current revenue?

    The current revenue for Endomedix is .

  • How much funding has Endomedix raised over time?

    Endomedix has raised $5.36M.

  • Who are Endomedix’s investors?

    Texas Medical Center, Central Texas Angel Network, Neuvation Ventures, Symbiotic Ventures, and Ignite Healthcare Network are 5 of 10 investors who have invested in Endomedix.

  • Who are Endomedix’s competitors?

    Baxter International, Integra LifeSciences Holdings, and Pfizer are competitors of Endomedix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process